Patents Examined by Yih-Horng Shiao
  • Patent number: 12291582
    Abstract: A process for producing a crosslinked cellulose ether including the steps of (i) contacting at least one cellulose material with a mixture comprising (ia) at least one crosslinking agent and (ib) at least one alkalization reagent to form an activated cellulose material; and (ii) contacting the activated cellulose material of step (i) with at least one etherification reagent; wherein the at least one etherification reagent reacts with the activated cellulose material to form the crosslinked cellulose ether; and a crosslinked cellulose ether produced by the above process.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: May 6, 2025
    Assignee: DOW GLOBAL TECHNOLOGIES LLC
    Inventors: Alexandra Hild, Jöerg Neubauer, Sonja Menz, Matthias Sprehe, Michael Schreck
  • Patent number: 12291530
    Abstract: The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions.
    Type: Grant
    Filed: September 13, 2024
    Date of Patent: May 6, 2025
    Assignee: Ascletis Pharma (China) Co., Limited
    Inventors: Bin Liang, Jinzi Jason Wu, Bailing Yang
  • Patent number: 12291548
    Abstract: Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: May 6, 2025
    Assignee: Sperovie Biosciences, Inc.
    Inventors: Radhakrishnan P. Iyer, Geeta Meher, Sreerupa Challa, Shenghua Zhou
  • Patent number: 12285421
    Abstract: The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3-{5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole (Compound-1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, and behavioral and psychological symptoms of dementia such as apathy/indifference, agitation, aggression, depression, anxiety, irritability/lability, dysphoria, aberrant motor behavior, delusions, hallucinations, elation/euphoria, psychosis, disinhibition, sleep and night time behavior disorders or appetite and eating disorders. The present invention further provides use of the 5-HT4 receptor agonist in the manufacture of medicament intended for the treatment of the disorders described herein.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: April 29, 2025
    Assignee: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Venkata Ramalingayya Grandhi, Pradeep Jayarajan, Vijay Benade, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
  • Patent number: 12280032
    Abstract: Embodiments provided herein include methods, compositions, and uses of aromatic alcohols to increase the potency of antifungal agents.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: April 22, 2025
    Assignee: PACIFIC NORTHWEST RESEARCH INSTITUTE
    Inventors: Catherine Ludlow, Aimee M. Dudley, Zhihao Tan
  • Patent number: 12281099
    Abstract: The present invention relates to new isoindolinone or isobenzofuranone substituted indoles and derivatives of formula (I) wherein the groups R1 to R7, R10 and n have the meanings given in the claims and specification, their use as inhibitors of RAS-family proteins and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: April 22, 2025
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Mantoulidis, Andreas Gollner, Dirk Kessler, Laetitia Janine Martin, Harald Weinstabl
  • Patent number: 12268705
    Abstract: Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using ?-1,3/1,6-D-glucan derived from mycelium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising ?-1,3/1,6-D-glucan are also provided.
    Type: Grant
    Filed: August 9, 2023
    Date of Patent: April 8, 2025
    Assignee: PT. SAHABAT LINGKUNGAN HIDUP
    Inventors: Peter Sugita, Wiwiek Widyastuti Budiliantono, Aurelia Maxine Sugita
  • Patent number: 12269822
    Abstract: A compound of formula (I), (IA) or formula (II) or a composition comprising the compound of formula (I), (IA) or formula (II) in association with a veterinarily acceptable carrier are described. A method of controlling helminths using same is described.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: April 8, 2025
    Inventors: Alan Long, Hyoung Lee, Hannes Fiepko Koolman
  • Patent number: 12269840
    Abstract: The invention generally relates to an improved processes for the preparation of a cyclic dinucleotide which is useful as a STING agonist of the following formula (I), involving the use of compounds A and B.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: April 8, 2025
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael Anthony Schmidt, Bin Zheng, Benjamin M. Cohen, Amanda J. Rogers, Changxia Yuan, Jason J. Zhu, Chao Hang, Daniel S. Treitler, Adam Joseph Freitag, Geoffrey Eugene Purdum, Miao Yu, Melda Sezen Edmonds, Siwei Guo
  • Patent number: 12269784
    Abstract: The present disclosure relates to the production of biomass from at least one plastic polymer. More specifically, the present disclosure relates to use of a feed for production of biomass, wherein larvae of the family Pyralidae or of the family Tenebrionidae are fed on a feed comprising at least one plastic polymer, a related use of increasing pupation in a population of larva.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: April 8, 2025
    Assignee: NBTECH AB
    Inventors: Nathalie Berezina, Maxim Chapovalov
  • Patent number: 12269841
    Abstract: A method for producing an oligonucleotide, including a step of removing a temporary protecting group of a 5?-hydroxyl group by adding an acid to a protected oligonucleotide having a phosphorothioate (PS), phosphate (PO) or H-phosphonate moiety, and deacylating a by-product having an acylated 5?-hydroxyl group by solvolysis can complete a condensation reaction to improve a condensation yield, and can markedly reduce impurities such as single base deletion form (N-1mer) and the like.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: April 8, 2025
    Assignee: AJINOMOTO CO., INC.
    Inventors: Daisuke Takahashi, Taisuke Ichimaru, Kunihiro Hirai
  • Patent number: 12269756
    Abstract: Hydrogel nanobeads include an ionically crosslinked sulfated polysaccharide biopolymer such as a carrageenan. In an embodiment, the hydrogel nanobeads comprise kappa carrageenan (?Cg) and a metal ion crosslinking agent. In an embodiment, the metal ion crosslinking agent includes a metal ion selected from the group consisting of Zn2+, Fe2+, Fe3+, and Ti3+. The hydrogel nanobeads can be used for removal of pollutants in wastewater.
    Type: Grant
    Filed: October 9, 2024
    Date of Patent: April 8, 2025
    Assignee: KING SAUD UNIVERSITY
    Inventors: Javed Alam, Mansour Salah Alhoshan, Fekri Abdulraqeb Ahmed Ali, Arun Kumar Shukla
  • Patent number: 12264148
    Abstract: Provided are formulations of ivosidenib including a number of polymorphs. Further provided are formulations of ivosidenib containing a number of known impurities. Still further provided are stable compositions of ivosidenib.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: April 1, 2025
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Chong-Hui Gu, Jacob Paul Sizemore, Shijie Zhang
  • Patent number: 12264176
    Abstract: Allulose crystals are efficiently produced from an allulose syrup using seed crystals.
    Type: Grant
    Filed: December 7, 2022
    Date of Patent: April 1, 2025
    Assignee: Tate & Lyle Solutions USA LLC
    Inventors: Krishnan Viswanathan Iyer, James Gaddy, Jerry Lynn Turner, Brian Timothy Pohrte
  • Patent number: 12257263
    Abstract: Formulation of ectoparasiticidal and antibiotic “compositions into pharmaceutical compositions useful for the treatment of eyelid inflammation, in particular demodex related blepharitis and eye crusting.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: March 25, 2025
    Assignee: Tarsus Pharmaceuticals, Inc.
    Inventors: Tiang Hin Jerry Tan, Yong Ming Por
  • Patent number: 12257259
    Abstract: The present invention relates to nutritional compositions comprising 2?-Fucosyllactose (2?FL) for use in improving the gastrointestinal barrier. In particular, the present invention relates to improving gastrointestinal barrier in an infant, a young child or children aged above 3 years to 8 years.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: March 25, 2025
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Clara Lucia Garcia-Rodenas, Jane Mea M Natividad, Andreas Rytz, Sami Damak, Norbert Sprenger, Francis Foata, Florence Rochat, Claire Laurence Lucie Marie Boulange
  • Patent number: 12258426
    Abstract: The present disclosure relates to compositions comprising mixtures of hydroxypropyl-?-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-?-cyclodextrins.
    Type: Grant
    Filed: April 11, 2024
    Date of Patent: March 25, 2025
    Assignee: BEREN THERAPEUTICS P.B.C.
    Inventors: Steven Pfeiffer, Dustin McMinn, Gabor Benkovics
  • Patent number: 12258601
    Abstract: Disclosed herein are improved processes for making tagatose including the steps of converting F6P to T6P, catalyzed by a F6PE; and converting the T6P to tagatose, catalyzed by a T6PP, using enzymes with higher activities compared to F6PEs and T6PPs previously used in a process to produce tagatose.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: March 25, 2025
    Assignee: BONUMOSE, INC.
    Inventor: Daniel Joseph Wichelecki
  • Patent number: 12257240
    Abstract: Among others, the present invention provides methods and compositions for controlling blood glucose or weight, including a combination of (i) a therapeutically effective amount of berberine (BBR), or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof, including dihydroberberine (DHB); and (ii) vitamin B12. The combination effectively ameliorates BBR or DHB side effects, including VB12 reduction, gastrointestinal discomfort, and slowed bowel movements, by promoting transcobalamin II receptors synthesis, decreasing homocysteine levels and maintaining intestinal balance, including short chain fatty acids content, gut microbiota diversity and richness.
    Type: Grant
    Filed: August 23, 2022
    Date of Patent: March 25, 2025
    Assignee: NANJING NUTRABUILDING BIO-TECH CO., LTD.
    Inventors: Shawn Wells, Ronghua Yi, Mingru Wang, Kylin Liao
  • Patent number: 12251393
    Abstract: The present invention provides a composition comprising adenosine or adenosine triphosphate (ATP) acting as an absorption enhancer when combined with a nutritional material(s) such as nutrients, protein, peptides, vitamins, phytochemicals, minerals, fatty acids, or amino acids or a drug. Methods of administering ATP or adenosine to improve the bioavailability of a nutritional material(s) such as nutrients, protein, peptides, vitamins, phytochemicals, minerals, fatty acids, or amino acids or a drug are described.
    Type: Grant
    Filed: April 27, 2023
    Date of Patent: March 18, 2025
    Assignee: TSI Group Co., Ltd.
    Inventors: John Rathmacher, Lisa Pitchford, Shawn Baier, Larry Kolb, Naji Abumrad, Matthew Legge